

BioRestorative Therapies, Inc.
Form 8-K
March 06, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: March 6, 2014
(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada 000-54402 91-1835664
(State or Other (Commission File No.) (IRS Employer
Jurisdiction Identification
of Incorporation) Number)

5 5 5 33458
Heritage
Drive,
Jupiter,
Florida
(Address(Zip
of Code)
Principal
Executive
Offices)

Registrant's telephone number, including area code: (561) 904-6070

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

___ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: BioRestorative Therapies, Inc. - Form 8-K

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) BioRestorative Therapies, Inc. and Mark Weinreb, its Chief Executive Officer, have agreed that Mr. Weinreb's salary for the year ended December 31, 2013 was \$360,000 (a reduction from the \$600,000 in annual salary to which Mr. Weinreb was entitled) and that Mr. Weinreb will not receive any of the \$300,000 bonus for such year to which he was entitled.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES, INC.

Dated: March 6, 2014

By: /s/ Mark Weinreb
Mark Weinreb
Chief Executive Officer